The global surge in metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, presents a pressing public health dilemma. Affecting roughly one-third of the population worldwide, MASLD not only burdens liver function with fat accumulation but also triggers inflammation, fibrosis, and heightened cancer risk. Traditional therapeutic approaches have struggled with consistency and